<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>292</serviceExecutionTime><Drug id="5858"><DrugName>piclamilast</DrugName><DrugNamesKey><Name id="42757172">piclamilast</Name></DrugNamesKey><DrugSynonyms><Name><Value>piclamilast</Value><Types><Type>USAN</Type><Type>PINN</Type></Types></Name><Name><Value>RP-73401</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RPR-73401</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>144035-83-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19234">Rhone-Poulenc SA</CompanyOriginator><CompaniesSecondary><Company id="19234">Rhone-Poulenc SA</Company><Company id="19365">Rhone-Poulenc Rorer Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="5858" type="Drug"><TargetEntity id="207169" type="siDrug"></TargetEntity><TargetEntity id="197379" type="siDrug">Piclamilast</TargetEntity></SourceEntity><SourceEntity id="19234" type="Company"><TargetEntity id="4297429768" type="organizationId">Rhone-Poulenc Biochimie SA</TargetEntity></SourceEntity><SourceEntity id="19365" type="Company"><TargetEntity id="5036165108" type="organizationId">Rhone-Poulenc Rorer Inc</TargetEntity></SourceEntity><SourceEntity id="28" type="ciIndication"><TargetEntity id="10003246" type="MEDDRA"></TargetEntity><TargetEntity id="D001168" type="MeSH"></TargetEntity><TargetEntity id="-1504014133" type="omicsDisease"></TargetEntity><TargetEntity id="720" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="304" type="Action"><TargetEntity id="470" type="Mechanism">Phosphodiesterase PDE4 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="28">Arthritis</Indication><Indication id="31">Asthma</Indication></IndicationsSecondary><ActionsPrimary><Action id="304">PDE 4 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="646">Bronchodilator</Action></ActionsSecondary><Technologies><Technology id="559">Oral controlled release formulation</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="617">Aerosol formulation inhalant</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-11-29T15:20:50.000Z</LastModificationDate><ChangeDateLast>2006-11-23T14:24:41.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19234" linkType="Company"&gt;Rhone-Poulenc&lt;/ulink&gt; was developing piclamilast, a PDE4 inhibitor, as an oral formulation for the potential treatment of arthritis [&lt;ulink linkID="272136" linkType="reference"&gt;272136&lt;/ulink&gt;]; however, development was discontinued in 1996 [&lt;ulink linkID="449179" linkType="reference"&gt;449179&lt;/ulink&gt;]. Development of the compound as an anti-asthmatic had also been discontinued by 1996 [&lt;ulink linkID="215751" linkType="reference"&gt;215751&lt;/ulink&gt;]. It had reached phase II trials in an inhalable formulation in Europe and the US and phase I trials in Japan for this indication [&lt;ulink linkID="175440" linkType="reference"&gt;175440&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ARTHRITIS&lt;/subtitle&gt;In a multinational clinical study involving 35 arthritic patients, piclamilast caused a reduction in CRP and IL-6 serum levels, but not by a significant amount [&lt;ulink linkID="272136" linkType="reference"&gt;272136&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ASTHMA&lt;/subtitle&gt;In vivo administration of a dry powder formulation of piclamilast directly into the airways of guinea pigs and rats potently inhibits antigen responses; however, in the clinic, inhaled RP-73401 failed to modify FEV-1 in moderate asthmatics following a single oral dose of 800 microg. Increasing this dose was not possible due to increased side effects such as nausea and backache. The company was attempting to identify orally bioavailable compounds which are better tolerated for the treatment of asthma and arthritis [&lt;ulink linkID="333171" linkType="reference"&gt;333171&lt;/ulink&gt;], [&lt;ulink linkID="332607" linkType="reference"&gt;332607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; Piclamilast has been shown to block early- and late-phase reaction in an allergen-induced bronchospasm guinea pig model and reduce allergen-induced brochoconstriction by more than 50% [&lt;ulink linkID="317564" linkType="reference"&gt;317564&lt;/ulink&gt;], [&lt;ulink linkID="318120" linkType="reference"&gt;318120&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a murine model of antigen-induced BHR in response to iv methacholine in mice, repeated treatment with piclamilast (1 and 3 mg/kg sc) markedly reduced BHR and eosinophil number in BAL [&lt;ulink linkID="282173" linkType="reference"&gt;282173&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In 1999, results were published showing that piclamilast, administered orally or by inhalation, caused toxic effects in rats. A single oral administration at 50 mg/kg or a 5-day inhalation exposure at 1 mg/kg/day was associated with damage to the epithelium of nasal mucosa. In a 2-year inhalation study, rats treated with 0.5 or 1.0 mg/kg/day suffered olfactory neuroblastomas. However, other species tested, including mice and dogs, did not show these effects and it was concluded that metabolic activation of piclamilast in rat cells was responsible [&lt;ulink linkID="448130" linkType="reference"&gt;448130&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A new series of PDE4 inhibitors originating from piclamilast was reported in 1998. The original structure has been modified at the 3,4-dialkoxyphenyl group which has been replaced with a 2-substituted-7-methoxy-benzimidazole. The company aimed to retain the essential recognition elements but eliminate the possibility of oxidative metabolism, increase water solubility and further define the underlying pharmacophore. Results showed improved oral bioavailability [&lt;ulink linkID="301836" linkType="reference"&gt;301836&lt;/ulink&gt;]. N-oxide derivatives also demonstrate low nanomolar IC50 values for PDE4 inhibition and excellent in vivo activity for inhibition of TNF-alpha levels in LPS challenged mice (mouse endotoxemia model). They also showed substantial improvement in frequency of emesis, the most commonly observed side effect piclamilast [&lt;ulink linkID="304265" linkType="reference"&gt;304265&lt;/ulink&gt;]. The analogs are claimed to be from 10,000- to 50-fold more selective for PDE4 than for PDE1, PDE2 or PDE5 [&lt;ulink linkID="287016" linkType="reference"&gt;287016&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vitro studies showed piclamilast decreases TNF release from LPS stimulated monocytes with an IC50 in the low nM range. It has a 1900-fold selectivity for PDE4 over other isotypes, and demonstrated an IC50 of 35 microM in metacholine-induced bronchoconstriction [&lt;ulink linkID="188256" linkType="reference"&gt;188256&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Dr Lorenzo Pradella, Senior Scientist, &lt;ulink linkType="Company" linkID="20999"&gt;Zambon Group SpA&lt;/ulink&gt;, Bresso, Milan, Italy&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;3 October 1997&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Five distinct phosphodiesterase (PDE) isoenzymes have been identified, each one having a number of subtypes. PDE4 suppresses the functions of several cell types implicated in allergic and inflammatory disorders and has also been detected in airway smooth muscle. Inhibition of PDE4 in activated eosinophils, the predominant inflammatory cells in asthma, has lead to the therapeutic potential of PDE4 inhibitors. Similarly, the inhibition of tumor necrosis factor-alpha (TNF-alpha) production from monocytes suggests a potential role for PDE4 inhibitors in a range of conditions, including arthritis and septic shock.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The SAR of a series of N-heterocyclic benzamides, including &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; (RP-73401) has been described [&lt;ulink linkType="reference" linkID="159713"&gt;159713&lt;/ulink&gt;], the synthesis of which requires four steps. SAR is based on the inhibition of the cytosolic PDE4 from pig aorta (IC50 = 1 nM). Selected compounds have been tested in vitro to evaluate their ability to inhibit superoxide generation in guinea pig eosinophils (&lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; IC50 = 24 nM), and in vivo for their activity in inhibiting histamine-induced bronchospasm in anesthetized guinea pigs (&lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt;, 50 microg gave 78% inhibition). &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; was the most potent anti-inflammatory/bronchodilating agent of the series. The synthesis of more bioavailable PDE4 inhibitors, derived from &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; has been pursued, and amongst the second generation inhibitors, &lt;ulink linkType="Drug" linkID="13385"&gt;RPR-114597&lt;/ulink&gt; (Rhone-Poulenc Rorer) has a bioavailability of 77% [&lt;ulink linkType="reference" linkID="220606"&gt;220606&lt;/ulink&gt;].&lt;br/&gt;  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; is a very potent inhibitor of PDE4, with IC50 values for PDE4 from guinea pig eosinophils and aortic smooth muscle of 0.7 and 1.2 nM, respectively [&lt;ulink linkType="reference" linkID="183614"&gt;183614&lt;/ulink&gt;]. It is approximately 200- to 2000-fold more potent than &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; (Schering) on the catalytic site (IC50 = 186 and 3162 nM in guinea pig eosinophils and aortic smooth muscle, respectively) [&lt;ulink linkType="reference" linkID="183614"&gt;183614&lt;/ulink&gt;] and is comparable to &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; on the high affinity &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; binding site (KD = 1.9 and 7.7 nM, respectively) [&lt;ulink linkType="reference" linkID="178535"&gt;178535&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; was shown to have a 1900-fold selectivity for PDE4 compared to other PDE isoenzymes [&lt;ulink linkType="reference" linkID="183614"&gt;183614&lt;/ulink&gt;]. It shows the same potency for inhibiting PDE4 from monocytes, eosinophils and T-cells [&lt;ulink linkType="reference" linkID="254490"&gt;254490&lt;/ulink&gt;]. On recombinant &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; is equipotent on the subtypes A, B and D, and about 10-fold less potent on the subtype C [&lt;ulink linkType="reference" linkID="254490"&gt;254490&lt;/ulink&gt;]. It is also equipotent on PDE4 from guinea pig eosinophils and from pig aorta [&lt;ulink linkType="reference" linkID="224635"&gt;224635&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; induces relaxation of isolated guinea pig trachea under basal tone (EC50 = 9 nM), precontracted with histamine (EC50 = 2 nM), methacholine (EC50 = 29 nM) or leukotriene D4 (EC50 = 4 nM) [&lt;ulink linkType="reference" linkID="177606"&gt;177606&lt;/ulink&gt;]. Similar results are reported in another study comparing other compounds [&lt;ulink linkType="reference" linkID="218589"&gt;218589&lt;/ulink&gt;] in which the rank order is salbutamol &gt; &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; = &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; &gt;/= &lt;ulink linkType="Drug" linkID="6575"&gt;CDP-840&lt;/ulink&gt; &gt; aminophylline. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; also induces relaxation of human isolated bronchial smooth muscle under basal tone, or precontracted with acetylcholine but with a low maximal response (Emax approximately 40%) [&lt;ulink linkType="reference" linkID="224265"&gt;224265&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; is significantly more potent than &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; in potentiating cAMP accumulation in human monocytes (IC50 = 1.5 and 313 nM) [&lt;ulink linkType="reference" linkID="224627"&gt;224627&lt;/ulink&gt;], but only three- fold more potent than &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; in enhancing isoprenaline-induced cAMP accumulation in guinea pig eosinophils [&lt;ulink linkType="reference" linkID="224635"&gt;224635&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; inhibits several in vitro functions of immune and inflammatory cells, including FMLP-induced leukotriene C4 production from human eosinophils (IC50 = -8.78 log M, &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; = -8.3 log M) [&lt;ulink linkType="reference" linkID="224633"&gt;224633&lt;/ulink&gt;], leukotriene B4-induced superoxide generation (IC50 = 25 nM), major basic protein (MBP) release (IC50 = 115 nM) and eosinophil cationic protein (ECP) release (IC50 = 7 nM) from guinea pig eosinophils [&lt;ulink linkType="reference" linkID="183614"&gt;183614&lt;/ulink&gt;], TNF-alpha production from human monocytes (IC50 = 6.9 nM, &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; = 490 nM) [&lt;ulink linkType="reference" linkID="224627"&gt;224627&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="224611"&gt;224611&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="188180"&gt;188180&lt;/ulink&gt;],  IL-2 release from murine splenocytes (IC50 = 0.46 nM, &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; = 540 nM) [&lt;ulink linkType="reference" linkID="254495"&gt;254495&lt;/ulink&gt;] [&lt;ulink linkType="reference" linkID="188180"&gt;188180&lt;/ulink&gt;], but not IL-5 release [&lt;ulink linkType="reference" linkID="188180"&gt;188180&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; also increases IL-10 production from human monocytes [&lt;ulink linkType="reference" linkID="224611"&gt;224611&lt;/ulink&gt;] and inhibits the chemotactic response of human polymorphonuclear leukocytes (IC50 = 232 nM, &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; = 121 nM) [&lt;ulink linkType="reference" linkID="254496"&gt;254496&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; is more potent in inhibiting TNF-alpha production from monocytes, than from macrophages [&lt;ulink linkType="reference" linkID="254498"&gt;254498&lt;/ulink&gt;], and is equipotent to &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; on human basophils, but inactive on mast cells [&lt;ulink linkType="reference" linkID="254497"&gt;254497&lt;/ulink&gt;]. Finally, both &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; inhibit complement C5a-induced degranulation of human eosinophils in the presence of salbutamol, with a potency which is two-fold lower than in a cell-free system [&lt;ulink linkType="reference" linkID="224630"&gt;224630&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; (0.4 - 400 microg/kg, intratracheally) inhibits antigen-induced bronchospasm in sensitized guinea pigs, with an ID50 = 7 microg/kg (&lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; ID50 = 5 microg/kg) and in anesthetized rats (ID50 = 100 microg/kg). &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; also inhibits the bronchospasm induced by histamine, methacholine, and leukotriene D4 in anesthetized guinea pigs [&lt;ulink linkType="reference" linkID="177606"&gt;177606&lt;/ulink&gt;]. At bronchodilating doses, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; has no effect on heart rate and blood pressure [&lt;ulink linkType="reference" linkID="177606"&gt;177606&lt;/ulink&gt;]. Considering hyper-reactivity, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; (0.02 - 100 microg/kg, iv), inhibits PAF-induced bronchial hyper-reactivity in anesthetized guinea pig (ID50 = 50 microg/kg), but not ozone-induced hyper-reactivity when administered at 10 microg/kg, ip, in anesthetized guinea pig [&lt;ulink linkType="reference" linkID="218589"&gt;218589&lt;/ulink&gt;]. Concerning antiinflammatory activity, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; reduces the total cell and eosinophil recruitment (ID50 = 3.2 microg/kg, iv) in the bronchoalveolar lavage fluid (BAL) of ovalbumin-sensitized guinea pigs [&lt;ulink linkType="reference" linkID="177606"&gt;177606&lt;/ulink&gt;]. Similar results are reported in other studies using a different regimen of treatment [&lt;ulink linkType="reference" linkID="254510"&gt;254510&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; (5 mg/kg, ip) reduced both eosinophil numbers and eosinophil peroxidase levels [&lt;ulink linkType="reference" linkID="207513"&gt;207513&lt;/ulink&gt;]. When administered po, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; (0.3 - 10 mg/kg) is 10- to 100-times less potent than &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6575"&gt;CDP-840&lt;/ulink&gt; (Celltech) in reducing IL-5-induced pleural eosinophilia in rats [&lt;ulink linkType="reference" linkID="254510"&gt;254510&lt;/ulink&gt;], but equipotent to &lt;ulink linkType="Drug" linkID="4268"&gt;rolipram&lt;/ulink&gt; in suppressing serum TNF-alpha levels in LPS-challenged Balb/C mice (ID50 = 1 and 2.5 mg/kg) [&lt;ulink linkType="reference" linkID="188180"&gt;188180&lt;/ulink&gt;]. Moreover, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; (10 mg/kg, ip) reduces histamine and ovalbumin-induced skin edema in guinea pigs [&lt;ulink linkType="reference" linkID="254511"&gt;254511&lt;/ulink&gt;]. In arthritis models, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; reduced the incidence and the severity of collagen induced arthritis in mice (10 or 30 mg/kg, ip, for seven days) and of streptococcal cell wall-induced arthritis in rats (10 or 20 mg/kg, po, for seven days) [&lt;ulink linkType="reference" linkID="224272"&gt;224272&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No metabolism studies have been published. However, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; has demonstrated limited bioavailability in rodents, due to extensive first pass metabolism [&lt;ulink linkType="reference" linkID="217902"&gt;217902&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No toxicity data have been published. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;No data on safety profiles have been published. The method for the determination of &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; in human plasma is available [&lt;ulink linkType="reference" linkID="185032"&gt;185032&lt;/ulink&gt;], although no data on the pharmacokinetic profile of the drug have been disclosed.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt;, 1200 microg, inhaled for 15 min, failed to prevent the early phase of allergen-induced bronchoconstriction in 11 mild to moderate asthmatics [&lt;ulink linkType="reference" linkID="254508"&gt;254508&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt;, at 50 and 100 microg, inhaled bid for six weeks did not improve FEV1, methacoline-induced airway responsiveness and nitric oxide exhalation in asthmatics [&lt;ulink linkType="reference" linkID="254512"&gt;254512&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In trials for rheumatoid arthritis, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt;, 200 or 400 microg, tid for 28 days, induced a positive trend in patients, but the results were statistically insignificant [&lt;ulink linkType="reference" linkID="254507"&gt;254507&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;No selective PDE4 inhibitors are currently marketed. A number have entered phase I clinical trials, but most have been discontinued, probably due to side-effects. Although few clinical studies have been carried out to fully ascertain the side-effect profile, nausea and vomiting seem to be the major adverse effects observed. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; is a very potent and selective PDE4 inhibitor. The in vitro and in vivo pharmacology profile is clearly in agreement with its mechanism of action, with &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; inducing bronchodilation and antiinflammatory effects through the inhibition of PDE4. Because of its low bioavailability, it is preferentially administered by inhalation. Unfortunately, in clinical studies, &lt;ulink linkType="Drug" linkID="5858"&gt;piclamilast&lt;/ulink&gt; did not induce the expected effects after both acute and repeated inhalation treatment. &lt;ulink linkType="Drug" linkID="5858"&gt;Piclamilast&lt;/ulink&gt; seems to have been discontinued as an antiasthmatic agent, however, it is currently being considered as an oral treatment for arthritis [&lt;ulink linkType="reference" linkID="215751"&gt;215751&lt;/ulink&gt;].&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-10-08T00:00:00.000Z</StatusDate><Source id="215751" type="CONFERENCE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="28">Arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-01T00:00:00.000Z</StatusDate><Source id="449179" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19234">Rhone-Poulenc SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="28">Arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-01T00:00:00.000Z</StatusDate><Source id="449179" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-10-08T00:00:00.000Z</StatusDate><Source id="215751" type="CONFERENCE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19234">Rhone-Poulenc SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-10-08T00:00:00.000Z</StatusDate><Source id="215751" type="CONFERENCE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19234">Rhone-Poulenc SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="28">Arthritis</Indication><Source id="215751" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19234">Rhone-Poulenc SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><Source id="175440" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="28">Arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-10-08T00:00:00.000Z</StatusDate><Source id="215751" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="28">Arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-10-08T00:00:00.000Z</StatusDate><Source id="215751" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><Source id="175440" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19365">Rhone-Poulenc Rorer Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><Source id="175440" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01522"><Name>PDE 4</Name><SwissprotNumbers><Swissprot>Q22000</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=745015" linkType="reference" linkID="745015"&gt;745015&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>COc1ccc(cc1OC2CCCC2)C(=O)Nc3c(cncc3Cl)Cl</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1021128" number="WO-2009147169" title="Pharmaceutical compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia"></PatentFamily><PatentFamily id="1738063" number="WO-09212961" title="Benzamides."></PatentFamily><PatentFamily id="242593" number="WO-09404133" title="Inhalation Powder Containing Antistatic Agent"></PatentFamily><PatentFamily id="401007" number="WO-2004062671" title="PDE4 inhibitors for the treatment of neoplasms of lymphoid cells"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Denis Diderot" id="25808"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Istituto di Ricerche Farmacologiche Mario Negri" id="26961"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>